KYOTO UNIVERSITY OPEN INNOVATION INSTITUTE


Associated tags: Kyoto University, Probability, Drug development, Cancer, Biomarker, RNA, Patient, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Fujitsu, Diagnosis, Therapy, Gene, Genome, Pharmaceutical industry, Chordia

Fujitsu, Kyoto University, and Chordia Therapeutics launch AI trials to discover biomarkers for new cancer drugs

Retrieved on: 
Wednesday, May 17, 2023

This information will assist researchers working to discover biomarkers for patient stratification that can be used to determine the efficacy of cancer treatments that target RNA regulatory stress (5), under development by Kyoto University and Chordia since May 2018.

Key Points: 
  • This information will assist researchers working to discover biomarkers for patient stratification that can be used to determine the efficacy of cancer treatments that target RNA regulatory stress (5), under development by Kyoto University and Chordia since May 2018.
  • Through this demonstration, Fujitsu, Kyoto University, and Chordia Therapeutics aim to realize new cancer treatments personalized to individual patients' genetic characteristics, cancer symptoms and progression, ultimately improving patient outcomes and well-being.
  • A variety of biomarkers are currently used in the medical field for preventative care, diagnosis, and treatment selection of cancer.
  • In clinical trials, biomarkers make it possible for drug development researchers to focus on specific characteristics, improving the likelihood of developing successful and effective new drug candidates.